| Systemic inhibition of PTPN22 augments anticancer immunity WJ Ho, S Croessmann, J Lin, ZH Phyo, S Charmsaz, L Danilova, ... The Journal of Clinical Investigation 131 (17), 2021 | 33 | 2021 |
| Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy J Yang, Q Lv, W Wei, Z Yang, J Dong, R Zhang, Q Kan, Z He, Y Xu Drug Delivery 25 (1), 807-814, 2018 | 33 | 2018 |
| A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity S Liang, E Tran, X Du, J Dong, H Sudholz, H Chen, Z Qu, ND Huntington, ... Nature Communications 14 (1), 4524, 2023 | 31 | 2023 |
| Small molecule degraders of protein tyrosine phosphatase 1B and T‐cell protein tyrosine phosphatase for cancer immunotherapy J Dong, J Miao, Y Miao, Z Qu, S Zhang, P Zhu, F Wiede, BA Jassim, Y Bai, ... Angewandte Chemie International Edition 62 (22), e202303818, 2023 | 20 | 2023 |
| SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late‐onset Alzheimer's disease CD Jesudason, ER Mason, S Chu, AL Oblak, J Javens‐Wolfe, M Moussaif, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 9 (4 …, 2023 | 5 | 2023 |
| Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity J Miao, Y Bai, Y Miao, Z Qu, J Dong, RY Zhang, D Aggarwal, BA Jassim, ... Molecules 28 (19), 6947, 2023 | 4 | 2023 |
| Discovery of a selective TC-PTP degrader for cancer immunotherapy J Miao, J Dong, Y Miao, Y Bai, Z Qu, BA Jassim, B Huang, Q Nguyen, ... Chemical Science 14 (44), 12606-12614, 2023 | 4 | 2023 |
| Targeted covalent inhibition of small CTD phosphatase 1 to promote the degradation of the REST Transcription factor in human cells B Medellin, W Yang, S Konduri, J Dong, S Irani, H Wu, WL Matthews, ... Journal of medicinal chemistry 65 (1), 507-519, 2021 | 4 | 2021 |
| Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases J Dong, BA Jassim, KL Milholland, Z Qu, Y Bai, Y Miao, J Miao, Y Ma, ... Journal of Medicinal Chemistry, 2024 | 2 | 2024 |
| A target enablement package for the inhibition of SHIP1 as a therapeutic strategy for the treatment of Alzheimer’s disease TI Richardson, CD Jesudason, KL Lobb, GL Durst, B Clayton, SM Massey, ... Alzheimer's & Dementia 18, e068781, 2022 | 2 | 2022 |
| Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers Y Miao, Y Bai, J Miao, AA Murray, J Lin, J Dong, Z Qu, RY Zhang, ... The Journal of Clinical Investigation 134 (15), 2024 | | 2024 |
| Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy Z Qu, Y Bai, J Dong, Z Zhang, B Huang, Y Miao, AW Tao, PS Low, ... Cancer Research 84 (6_Supplement), 4505-4505, 2024 | | 2024 |
| Discovery of the first-in-class SHP1 covalent inhibitor for cancer immunotherapy Z Qu, FN Meke, Z Zhang, Y Bai, AD Krabill, CS Muli, BA Jassim, J Dong, ... Cancer Research 84 (6_Supplement), 1973-1973, 2024 | | 2024 |
| Off-target autophagy inhibition by SHP2 allosteric inhibitors and therapeutic implications for aberrant RAS-driven cancers Y Miao, Y Bai, J Miao, AA Murray, J Lin, J Dong, Z Qu, RY Zhang, ... Cancer Research 84 (6_Supplement), 1969-1969, 2024 | | 2024 |
| Protein tyrosine phosphatases as emerging targets for cancer immunotherapy Z Qu, J Dong, ZY Zhang British Journal of Pharmacology, 2023 | | 2023 |
| Discovery and Evaluation of Novel Ship-1 Inhibitors ZY Zhang, J Miao, J Lin, J Dong, O Amarasinghe, ER Mason, S Chu, Z Qu, ... Available at SSRN 4934996, 0 | | |
